For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of Vyndamax and the formulated version represents a genuine breakthrough . These novel therapies protect the transthyretin protein, preventing its damaging build-up and lessening the severity of the condition . People are now experiencing improve